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The three EglN prolyl hydroxylases (EglN1, EglN2, and EglN3) regulate the stability of the HIF transcription factor.
We recently showed that loss of EglN2, however, also leads to down-regulation of Cyclin D1 and decreased cell
proliferation in a HIF-independent manner. Here we report that EglN2 can hydroxylate FOXO3a on two specific
prolyl residues in vitro and in vivo. Hydroxylation of these sites prevents the binding of USP9x deubiquitinase,
thereby promoting the proteasomal degradation of FOXO3a. FOXO transcription factors can repress Cyclin D1
transcription. Failure to hydroxylate FOXO3a promotes its accumulation in cells, which in turn suppresses Cyclin
D1 expression. These findings provide new insights into post-transcriptional control of FOXO3a and provide a new
avenue for pharmacologically altering Cyclin D1 activity.
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The HIF transcription factor, which consists of a labile
a subunit and a stable b subunit, is a master regulator
of genes that promote adaptation to hypoxia, including
genes linked to metabolism, angiogenesis, and prolifera-
tion (Semenza 2013). HIF provided the first example of
the use of prolyl hydroxylation as an intracellular signal.
Specifically, HIF1a is hydroxylated on prolyl residues
402 and 564 by members of the EglN prolyl hydroxylase
(also called PHD prolyl hydroxylase) family when oxygen is
plentiful (Ivan et al. 2001; Jaakkola et al. 2001; Masson et al.
2001; Kaelin and Ratcliffe 2008). Prolyl-hydroxylated HIFa
binds to the von Hippel-Lindau (VHL) E3 ligase complex,
which polyubiquitylates HIFa and targets it for proteasomal
degradation (Kaelin and Ratcliffe 2008).
There are three EglN family members in humans and
mice (EglN1, EglN2, and EglN3). Their enzymatic activity
requires oxygen, ascorbic acid, iron, and a-ketoglutarate
(a-KG). Under hypoxic conditions, EglNs lose their activ-
ity and fail to hydroxylate HIFa, which leads to HIFa
stabilization (Kaelin 2005; Kaelin and Ratcliffe 2008). HIFa
then forms a complex with its binding partner, HIF1b
(ARNT); translocates into the nucleus; binds to target
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genes containing hypoxia response elements (HREs); and
activates their transcription (Kaelin 2005; Kaelin and
Ratcliffe 2008). Notably, the oxygen Km values for the
EglN prolyl hydroxylases are slightly above atmospheric
oxygen (Epstein et al. 2001; Hirsila et al. 2003; Kaelin and
Ratcliffe 2008). As a result, they are poised to act as oxygen
sensors, coupling changes in oxygen availability to changes
in HIF-dependent transcription.
EglN1 is clearly the primary HIF prolyl hydroxylase
under normal conditions based on studies in cell culture
and with genetically engineered mice (Berra et al. 2003;
To and Huang 2005; Takeda et al. 2006; Minamishima
et al. 2008). Perhaps for this reason, EglN1 is required for
embryonic development, whereas EglN2/ and EglN3/
mice are viable (Takeda et al. 2006, 2007; Minamishima
et al. 2008). EglN2 and EglN3, however, contribute to HIFa
regulation under certain conditions, such as following
EglN1 inactivation (Minamishima et al. 2009).
There is also mounting indirect evidence that EglN2
and EglN3 have HIF-independent functions. For example,
EglN2 hydroxylase activity regulates Cyclin D1 accumu-
lation and proliferation in a HIF-independent manner,
and EglN3 can promote apoptosis in a HIF-independent
manner (Lee et al. 2005; Bishop et al. 2008; Zhang et al.
2009; Tennant and Gottlieb 2010). However, the EglN2
and EglN3 hydroxylation targets responsible for these
two phenotypes have remained elusive. For example,
EglN2 appears to control Cyclin D1 at the mRNA level,
and there is no evidence that EglN2 hydroxylates Cyclin
D1 directly (Zhang et al. 2009).
A number of groups have attempted to identify novel
EglN targets, including EglN2 and EglN3 targets. Taylor
and coworkers (Cummins et al. 2006) provided indirect
evidence that IkBKB is hydroxylated by EglN2, which
could potentially contribute to negative regulation of
NFkB by EglN2. Stamler and colleagues (Xie et al. 2009)
discovered that b2-adrenergic receptor could be hydrox-
ylated by EglN3 and subsequently ubiquitylated by pVHL.
Semenza and colleagues (Luo et al. 2011) reported that
PKM2 hydroxylation by EglN3 promotes its binding to
HIF1 and enhances the transactivation of HIF1 target genes.
For many of these and other putative EglN substrates, it has
been difficult to demonstrate hydroxylation both in vitro
and in vivo, possibly due to technical factors.
The FOXO transcription factors suppress cell prolifer-
ation and cell survival by transcriptionally activating
specific gene targets that are linked to diverse cancer
regulatory pathways (Greer and Brunet 2005; Huang and
Tindall 2007). Activation of PI3K by extracellular growth
signals leads to FOXO phosphorylation at three conserved
Ser/Thr sites by AKT, whereupon the FOXOs are trans-
located to the cytoplasm and degraded (Greer and Brunet
2005; Huang and Tindall 2007). The role of the FOXOs in
cancer has recently received increasing support from
genetic studies in mice and human tumors (Paik et al.
2007; Cancer Genome Atlas Research Network 2008).
Identification of EglN substrates by unbiased mass
spectrometry methods has so far proved challenging. This
might relate to low abundance of the substrates, low
affinities of the enzyme–substrate interactions, and the
fact that both hydroxylation and spontaneous oxidation
lead to the same change in mass (+16). We adapted
a previously reported 96-well decarboxylation assay to
screen for proteins that can be hydroxylated by EglN2 in
vitro (Zhang et al. 1999). We focused on 1000 proteins
previously linked to breast cancer because EglN2/mice
exhibit mammary gland hypoproliferation and because
loss of EglN2 inhibits breast cancer growth (Witt et al. 2006;
Zhang et al. 2009). We identified FOXO3a as an EglN2
prolyl hydroxylase substrate. Prolyl hydroxylation by EglN2
destabilizes FOXO3a by displacing the deubiquitinase
USP9x. Consequently, loss of EglN2 leads to the accumu-
lation of FOXO3a, which suppresses Cyclin D1.
Results
Screen for novel EglN2 substrates
To screen for EglN2 substrates, we modified a previously
published in vitro hydroxylation assay that can be used
in a 96-well plate format (Zhang et al. 1999). This assay
is based on the knowledge that hydroxylation by a-KG-
dependent dioxygenases results in the decarboxylation of
a-KG and the release of CO2. Hydroxylation in the pres-
ence of a-KG radiolabeled with 14C at the a carbon
position leads to the release of radioactive CO2, which
can then be captured with filters that are presaturated
with Ca(OH)2 and tightly clamped to each plate. CO2
release, quantified with a phosphoimager, provides a mea-
sure of hydroxylation in each well (Fig. 1A).
All three EglN family members can hydroxylate syn-
thetic HIF1a peptides in vitro (Bruick and McKnight
2001; Epstein et al. 2001; Ivan et al. 2001). In pilot
experiments, we confirmed that this 96-well plate assay
could detect hydroxylation of a wild-type HIF1a peptide
(corresponding to HIF1a residues 556–575) over a range of
peptide, enzyme, and a-KG concentrations (Fig. 1B). Con-
versely, a synthetically prehydroxylated analog of this
HIF1a peptide (Pro564-OH) served as a negative control
in these experiments (Fig. 1B).
Next, we confirmed that this assay could detect hydrox-
ylation of full-length HIF2a produced using wheat germ
extracts. In these experiments, increasing amounts of
plasmid DNA suitable for in vitro transcription and trans-
lation were added to fixed amounts of wheat germ extract,
which was then used in the hydroxylation assays. Wheat
germ extract programmed to produce HIF2a, but not p53,
produced hydroxylation signals above background over
a range of plasmid concentrations (0.1–1.0 mg) (Fig. 1C,D).
We next tested the in vitro translation products of
;1000 cDNAs previously linked to breast cancer (Witt
et al. 2006). Each cDNA was tested in quadruplicate in
separate plates (one cDNA per well per plate 3 four
plates). Wild-type HIF2a as well as a HIF2a variant in
which its two prolyl hydroxylation sites have been
changed to alanine (HIF2a dPA) (Kim et al. 2006) were
included as positive and negative controls, respectively,
in each plate. FOXO3a consistently produced a hydroxyl-
ation signal despite being produced at lower levels than
HIF2a (Fig. 1E–G). Another FOXO family member, FOXO1,
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as well as IkBKB also produced hydroxylation signals (Fig.
1E–G.). We focused on FOXO3a because it consistently
produced stronger hydroxylation signals than did either
FOXO1 or IkBKB and because FOXO3a suppresses the
proliferation of a variety of cell lineages, including mam-
mary cells, which are known to be affected by EglN2 loss
(Hu et al. 2004; Yang et al. 2008; Lin et al. 2011).
Hydroxylation of FOXO3a by EglN2
To determine whether FOXO3a can be hydroxylated by
EglN2 in vivo, we treated T47D breast cancer cells with
the prolyl hydroxylase inhibitor DMOG, the proteasome
inhibitor MG132, both, or neither (vehicle alone). Fol-
lowing FOXO3a and HIF1a immunoprecipitation, West-
ern blots were performed to examine FOXO3a and HIF1a
hydroxylation using an anti-hydroxyproline antibody (Pan-
P-OH). In multiple independent experiments, we detected
increased HIF1a and FOXO3a prolyl hydroxylation sig-
nals upon MG132 treatment, which was abrogated by
concurrent treatment with DMOG (Fig. 2A). The superior
signal to noise ratio for HIF1a hydroxylation using an
antibody that specifically recognizes hydroxylation of
HIF1a Pro564 (P-OH HIF 564) relative to the Pan-P-OH
antibody presumably reflects the higher affinity of the
former antibody relative to the latter (Fig. 2A). The in-
creased HIF1a prolyl hydroxylation signal with MG132
treatment was expected because HIF1a is rapidly degraded
following prolyl hydroxylation. The fact that FOXO3a
behaved similarly suggested that prolyl hydroxylation
likewise destabilizes FOXO3a.
Next, we used mass spectrometry to identify the
potential FOXO3a prolyl hydroxylation sites. Toward this
end, 293FT embryonic kidney cells were cotransfected to
produce either HA-HIF1a or HA-FOXO3a together with
Flag-EglN2 and treated with MG132. The HA-tagged
proteins were recovered by immunoprecipitation and
resolved by SDS–polyacrylamide gel electrophoresis.
The bands of interest were identified by Coomassie blue
staining, excised, and analyzed by mass spectrometry
(Fig. 2B; Supplemental Fig. S1A). Using this approach, we
identified hydroxylation of HIF1a Pro564, as expected, as
well as hydroxylation of FOXO3a prolyl residues 426 and
437, which are conserved across different species (Sup-
plemental Fig. S1B).
To determine whether EglN2 can hydroxylate these
sites in vitro, we first used our radioactive decarboxyl-
ation assay to confirm that EglN2 can hydroxylate a GST-
Figure 1. Screen for EglN2 substrates. (A) Biochemical basis for screen. Hydroxylation of a substrate by EglN2 is coupled to release and
capture of 14C-labeled CO2. (B) Hydroxylation assays performed with varying amounts of recombinant EglN2,
14C-aKG, and synthetic
HIF1a (556–575) peptides (wild-type or containing hydroxyproline at 564 position). (C) Hydroxylation assays using unprogrammed wheat
germ lysate (Empty) or wheat germ lysate programmed to produce His-tagged p53 or HIF2a. Hydroxylation assays with no EglN2 (first two
columns) or with EglN2 in the absence or presence of synthetic HIF1a peptides (columns 3,4) were included as controls. Increasing amounts
of plasmid DNA were used for in vitro transcription/translation, as indicated. (D) Immunoblot analysis of in vitro translation products used
in C. (E) Representative images from four independent hydroxylation assays. (F) Quantification of signal intensity in E (arbitrary units) after
subtracting signal intensity from the empty vector well. (G) Immunoblot analysis of in vitro translation products as in E.
Prolyl hydroxylation of FOXO3a by EglN2
GENES & DEVELOPMENT 1431
Figure 2. EglN2 prolyl hydroxylates FOXO3a in vivo and in vitro. (A) Immunoblot (IB) assays of whole-cell extracts (WCEs) and
immunoprecipitates (IPs) of T47D cells treated with either vehicle control, 1 mM DMOG, 10 mM MG132, or both 1 mM DMOG and 10
mM MG132. (B) 293FT cells were cotransfected to produce HA-FOXO3a and Flag-EglN2 and then treated with MG132. (Inset) HA-
FOXO3a was purified by anti-HA immunoprecipitation followed by SDS–polyacrylamide gel electrophoresis and Coomassie blue
staining. Shown are liquid chromatography-tandem mass spectrometry (LC-MS/MS) data for the excised FOXO3a band corresponding
to FOXO3a peptides hydroxylated at Pro426 or Pro437. The red ‘‘P’’ indicates a hydroxylated proline residue. (C,D) Coomassie blue
staining (C) and in vitro hydroxylation assays (D) with the indicated GST fusion proteins. Synthetic HIF1a peptides corresponding to
residues 556–575 were included as controls in D. P564-OH indicates 556–575 peptide hydroxylated at Pro564. (E) GST-FOXO3a (301–
674) was incubated with recombinant EglN2, resolved by SDS–polyacrylamide gel electrophoresis, and stained with Coomassie blue.
Shown are MS/MS data for the excised FOXO3a band corresponding to FOXO3a peptides hydroxylated at Pro426 or Pro437. The red ‘‘P’’
indicates a hydroxylated proline residue. The peak heights are the relative abundances of the corresponding fragment ions, with the
annotation of the identified matched N terminus-containing ions (b ions) in blue and C terminus-containing ions (y ions) in red.
FOXO3a fusion protein produced in Escherichia coli.
GST-HIF1a full-length and GST were included as positive
and negative controls, respectively (Fig. 2C,D). Next, we
performed in vitro hydroxylation assays with recombinant
EglN2 and either GST-HIF1a or a GST-FOXO3a fusion
protein containing FOXO3a residues 301–674 as sub-
strates. Mass spectrometry analysis confirmed hydroxyl-
ation of the same sites identified in vivo; namely, prolyl
residue 564 on HIF1a and prolyl residues 426 and 437 on
FOXO3a (Fig. 2E; Supplemental Fig. S1C,D). Hydroxyl-
ation of GST-FOXO3a was not detected when EglN2 was
omitted and was greatly diminished when prolyl residues
426 and 437 were mutated to alanines (Supplemental Fig.
S1E,F). We were unable to reproducibly detect hydroxyl-
ation of synthetic FOXO3a peptides spanning residues
400–440 or 420–444, possibly because additional FOXO3a
residues contact EglN2 or because hydroxylation of
FOXO3a by EglN2 requires a FOXO3 conformational
determinant that is not assumed by these peptides. A
similar situation has been described for the lysyl hydrox-
ylation of eRF1 by Jmjd4 (Feng et al. 2014).
EglN2 regulates FOXO3a abundance
Prolyl hydroxylation regulates HIF1a stability, and the
FOXO3a prolyl hydroxylation signal, like that of the
HIF1a prolyl hydroxylation signal, was increased by
proteasomal blockade in Figure 2A, suggesting that prolyl
hydroxylation regulates FOXO3a abundance. Consistent
with this idea, FOXO3a protein levels were increased in
primary mouse embryonic fibroblasts (MEFs), immortal-
ized MEFs, and mammary fat pads derived from EglN2/
female mice compared with littermate EglN2+/+ controls,
and these differences were abolished by exposure to
DMOG or hypoxia (Fig. 3A,B; Supplemental Fig. S2A).
The regulation of FOXO3a by EglN2 appeared to be post-
transcriptional because Foxo3a mRNA levels were simi-
lar in EglN2+/+ and EglN2/ MEFs (Supplemental Fig. S2B).
Notably, AKT activity, which regulates FOXO3a localiza-
tion and degradation (Brunet et al. 1999; Huang and
Tindall 2007), was not altered by EglN2 loss, as deter-
mined by AKT phosphorylation at Ser473 (Fig. 3A). This
suggests that regulation of FOXO3a by EglN2 and regu-
lation of FOXO3a by AKT are distinct from one another.
EglN1 loss, in contrast to EglN2 loss, did not induce
FOXO3a in MEFs and mammary fat pads despite modestly
up-regulated Foxo3a mRNA expression, indicating that
regulation of FOXO3a is specific to EglN2 (Supplemental
Fig. S2C–E).
Consistent with these results, down-regulation of EglN2
with two independent siRNAs and three independent
shRNAs up-regulated FOXO3a in T47D breast carcinoma
cells (Fig. 3C,D; Supplemental Fig. S2F). Similar results
were obtained in MCF-7 cells (Supplemental Fig. S2G). As
expected from the analysis of EglN1/ MEFs and mam-
mary fat pads, depletion of EglN1 by siRNA in T47D and
MCF-7 cells did not affect FOXO3a protein (Supplemental
Fig. S2F,G). Importantly, up-regulation of FOXO3a by
EglN2 RNAi was reversed by coexpression of an
shRNA/siRNA-resistant version of wild-type EglN2, but
not by a catalytically dead (H358A) EglN2 variant (Fig.
3E,F; Supplemental Fig. S2H). EglN2 depletion activated
FOXO3a-responsive promoters (FasL or FHRE) in lucifer-
ase-based reporter assays (Fig. 3G). The increased FOXO3a
reporter activity could be reversed by cotransfection with
an shRNA-resistant version of Flag-EglN2 (Fig. 3H).
We next asked whether up-regulation of FOXO3a could
account for our earlier observation that EglN2 loss causes
loss of Cyclin D1 (Zhang et al. 2009). To address this, we
stably infected T47D breast carcinoma cells to express an
effective FOXO3a shRNA or a control shRNA and then
transiently transfected them with siRNAs against EglN2
or control siRNA (Ctrl). Down-regulation of FOXO3a
blunted the effect of the EglN2 siRNA on Cyclin D1 levels
(Fig. 3I), suggesting that EglN2 loss leads to FOXO3a
accumulation, which then suppresses Cyclin D1. This
finding is consistent with previous reports that FOXO3a
suppresses Cyclin D1 (Ramaswamy et al. 2002; Schmidt
et al. 2002).
Regulation of FOXO3a by EglN2 is HIF-independent
Treatment of T47D cells with various pharmacological
prolyl hydroxylase inhibitors promoted the accumulation
of FOXO3a in EglN2-proficient cells but did not further
induce FOXO3a in cells already expressing high levels of
FOXO3a by virtue of shRNA-mediated EglN2 depletion
(Fig. 4A). Cells treated with MG132, which should induce
FOXO3a, were included as an additional control for com-
parison. These results further support that control of
FOXO3a by EglN2 is linked to EglN2 catalytic activity
(see Fig. 3F; Supplemental Fig. S2H). They left open,
however, the possibility that regulation of FOXO3a abun-
dance by EglN2 is an indirect consequence of activating
HIF, which is the canonical EglN substrate, instead of, or
in addition to, changes in FOXO3a hydroxylation. A link
between HIF and hypoxic induction of FOXO3a has been
suggested before (Bakker et al. 2007; Jensen et al. 2011).
To address this, we infected T47D or BT474 breast cancer
cells with shRNAs against ARNT, the critical binding
partner for HIFa’s transcriptional activity. Down-regula-
tion of EglN2 with siRNA in these cells still induced
FOXO3a (Fig. 4B; Supplemental Fig. S3A). Moreover, we
did not observe induction of HIF1a protein levels in breast
cancer cells after EglN2 loss alone (Fig. 4A), consistent
with EglN1 being the primary regulator of HIF1 under
most conditions (Berra et al. 2003). We did note that one
of the two ARNT shRNAs depressed basal FOXO3a levels
in BT474 breast cancer cells (Supplemental Fig. S3A). The
significance of this finding is unclear. Collectively, these
results suggest that control of FOXO3a by EglN2 is HIF-
independent.
Regulation of FOXO3 by EglN2 is post-transcriptional
To further understand how EglN2 regulates FOXO3a pro-
tein levels, we measured FOXO3a protein stability and
mRNA levels in cells depleted of EglN2. Loss of EglN2
prolonged FOXO3a protein stability, as determined by
cycloheximide chase experiments (Fig. 4C), but did not
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alter Foxo3a mRNA abundance (Fig. 4D; Supplemental
Fig. S2B), suggesting that the control of FOXO3a by EglN2
is post-transcriptional.
In support of this conclusion, we next infected two
different breast cancer cell lines (MCF-7 and T47D) with
a lentivirus encoding HA-tagged FOXO3a under the
control of a weak heterologous promoter (UBC). Treat-
ment of these cells with either prolyl hydroxylase in-
hibitors or a virus expressing an EglN2 shRNA promoted
the accumulation of HA-FOXO3a (Fig. 4E,F; Supplemen-
tal Fig. S3B). These interventions did not affect other HA-
tagged proteins expressed from this same lentiviral vector
(data not shown). In Figure 4F, treatment of MCF-7 cells
expressing the EglN2 shRNA with either DMOG or
MG132 led to further accumulation of HA-FOXO3a,
perhaps because down-regulation of EglN2 with the
shRNA was incomplete.
FOXO3a stability is regulated by prolyl hydroxylation
In order to narrow down the region of FOXO3a that is
responsible for its regulation by EglN2, we generated
different FOXO3a truncation mutants and tested their
responsiveness to DMOG and MG132. As shown in
Figure 5A, the region of FOXO3a corresponding to resi-
dues 1–500 was sufficient for induction by DMOG and
MG132, while FOXO3a polypeptides corresponding to
residues 1–200 and 1–300 were not induced by DMOG.
FOXO3a contains a nuclear localization signal (NLS)
between amino acids 242 and 259 that is important for
regulating its subcellular localization and protein stabil-
ity (Brunet et al. 1999; Tsai et al. 2007). Therefore, we
then tested an HA-FOXO3a variant corresponding to
FOXO3a residues 200–500 and found that this region
was sufficient to confer sensitivity to DMOG (Fig. 5B).
Since we determined that EglN2 hydroxylates FOXO3a
on Pro426 and Pro437 in vitro and in vivo, we next
generated full-length HA-FOXO3a variants in which
Pro426, Pro437, or both were changed to alanine. Muta-
tion of either Pro426 or Pro437 led to partial stabilization
of FOXO3a, which was further enhanced by DMOG
treatment (Fig. 5C). This effect was specific because
mutating another prolyl residue located nearby, Pro401,
did not alter FOXO3a abundance in these assays (Fig. 5C).
Importantly, mutating both Pro426 and Pro437 to alanine
(P426A;P437A) rendered FOXO3a insensitive to DMOG
treatment (Fig. 5D), EglN2 depletion (Fig. 5E), and hyp-
oxia (Fig. 5F), indicating that these two sites are necessary
and that either is sufficient for regulation of FOXO3a
protein stability by the EglN2 prolyl hydroxylase. Con-
sistent with these findings, mutations of both prolines
(P426A;P437A) significantly prolonged FOXO3a protein
Figure 3. FOXO3a protein abundance is regulated by EglN2 and links EglN2 to Cyclin D1. (A,B) Immunoblot analysis of primary MEFs
(A) and mammary fat pads (B) derived from EglN2+/+ and EglN2/ littermates. (C,D) Immunoblot analysis of T47D cells after transfection
with EglN2 siRNA (C) or infection with lentiviruses encoding EglN2 shRNAs. Unrelated nontargeting siRNA and shRNA sequences were
used as controls (Ctrl). (E) Immunoblot analysis of MCF-7 cells that were infected with a lentivirus encoding EglN2 shRNA or Ctrl shRNA
and, after drug selection, superinfected with a lentivirus encoding Flag-EglN2 (F-EglN2) under the control of a doxycycline-inducible
promoter. Increasing amounts of doxycycline were added to the cells 48 h before lysis as indicated by the triangle. (F) Immunoblot analysis
of primary MEF cells that were infected with a lentivirus encoding red fluorescent protein (RFP) or Flag-tagged EglN2 (wild-type or
H358A). (G,H) Luciferase reporter assay of T47D cells that were infected with a lentivirus encoding EglN2 shRNA (325 or 326) or Control
(Ctrl) shRNA followed by transfection with either FasL or FHRE reporter plasmid in the absence or presence of shRNA-resistant Flag-
EglN2 (F-EglN2) with TK-Renilla as an internal control. (I) Immunoblot analysis of T47D cells that were infected with a lentivirus
encoding FOXO3a shRNA or control (Ctrl) shRNA and then transfected with either EglN2 siRNA or Ctrl siRNA.
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stability compared with wild-type FOXO3a, as deter-
mined by cycloheximide chase experiments (Fig. 5G).
Prolyl hydroxylation of FOXO3a disrupts its
deubiquitylation by USP9x
Prolyl hydroxylation affects the stability of both HIF1a and
FOXO3a, the former because prolyl hydroxylation promotes
the binding of the pVHL ubiquitin ligase (Ivan et al. 2001;
Jaakkola et al. 2001). A number of FOXO3a ubiquitin ligases
have been reported, including b-TRCP and MDM2 (Yang
et al. 2008; Tsai et al. 2010). In pilot studies, however, we
found no evidence that hydroxylation promotes the binding
of these two ligases to FOXO3a (Supplemental Fig. S4A).
In an attempt to identify the molecular mechanism by
which FOXO3a stability is regulated by the EglN2 prolyl
Figure 4. Regulation of FOXO3a by EglN2 is post-transcriptional and HIF-independent. (A) Immunoblot analysis of T47D cells that
were infected with a lentivirus encoding EglN2 shRNA or control shRNA (Ctrl) and then treated with 200 mM CoCl2, 1 mM DMOG,
200 mM DFO, 10 mM MG132, or DMSO (Control) for 16 h. (B) Immunoblot analysis of T47D cells that were infected with a lentivirus
encoding either ARNT shRNA (3146) or Ctrl shRNA and, after drug selection, transfected with either EglN2 siRNA or Ctrl siRNA or
treated with 1 mM DMOG. (C) Immunoblot analysis of T47D cells that were infected with a lentivirus encoding either EglN2 shRNA
or Ctrl shRNA and then treated with 100 mg/mL cycloheximide (CHX) for the indicated amount of time. (D) Quantitative RT–PCR
(qRT–PCR) analysis of mRNA from T47D cells that were transfected with the indicated siRNAs. Error bars represent one SEM. (E,F)
Immunoblot analysis of MCF-7 cells that were infected with a lentivirus encoding HA-FOXO3a and, after hygromycin selection,
treated with either 10 mM MG132, 200 mM CoCl2, 200 mM DFO, 1 mM DMOG, or DMSO control for 16 h. (F) The cells were
superinfected with a lentivirus encoding EglN2 shRNA (327) or control shRNA after the initial hygromycin selection. The cells were
then placed under both hygromycin and puromycin selection and treated with DMOG, MG132, or vehicle control.
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Figure 5. FOXO3a prolyl hydroxylation sites govern FOXO3a stability. (A–E) Immunoblot analysis of T47D cells that were infected
with lentiviruses encoding the indicated HA-FOXO3a variants and then treated with either 1 mM DMOG, 10 mM MG132, or DMSO
control for 16 h (A–D) or transfected with EglN2 siRNA (1 or 4) or control siRNA (E). (WT) Wild-type. (C,D) Light or dark refers to
different exposure times. (F,G) Immunoblot analysis of T47D cells that were infected with a lentivirus encoding either wild-type
FOXO3a or P426A;P437A followed by hygromycin selection and treatment with either hypoxia for 16 h (F) or 100 mg/mL cycloheximide
(CHX) for the indicated amount of time (G). Light or dark refers to different exposure times.
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hydroxylase, we decided to identify protein whose binding
to FOXO3a could be influenced by FOXO3a hydroxyl-
ation. We treated T47D cells stably expressing HA-
FOXO3a under the control of the weak UBC promoter
with either DMOG or vehicle and then recovered the HA-
FOXO3a by immunoprecipitation. Mass spectrometry anal-
ysis of the immunoprecipitates from the DMOG-treated
samples (but not the vehicle control) revealed peptides
derived from FOXO3a, as expected, as well as two pep-
tides derived from the USP9x deubiquitinase (Supple-
mental Fig. S4B). Recovery of USP9x in such immuno-
precipitates was confirmed by Western blot analysis
(Supplemental Fig. S4C) but was substoichiometric, per-
haps reflecting a low affinity or fast off rate typical of
many enzyme–substrate interactions.
USP9x has been reported to stabilize various proteins
(Mcl-1, SMAD4, SMURF1, and Itch) involved in cancer by
preventing their degradation through the removal of con-
jugated ubiquitin (Mouchantaf et al. 2006; Dupont et al.
2009; Schwickart et al. 2010; Xie et al. 2013). Due to the
large size of USP9x, four different USP9x fragments, cor-
responding to N1 (residues 1–674), N2 (residues 675–1217),
C1 (residues 1218–2106), and C2 (residues 2107–2570),
were produced by in vitro translation and used in FOXO3a-
binding assays. The C2 fragment, but not the other frag-
ments, bound to GST-FOXO3 in vitro (Supplemental Fig.
S4D). Next, these same four USP9x fragments were pro-
duced as GST fusion proteins and used to capture full-
length FOXO3a produce by in vitro translation. GST-C2,
but not the other GST-USP9x, bound FOXO3a (Supplemen-
tal Fig. S4E,F). These results are consistent with an earlier
study that implicated the C2 region of USP9x in substrate
binding (Xie et al. 2013).
To determine whether USP9x regulates FOXO3a stabil-
ity, we infected T47D and MCF7 breast cancer cells with
five different hairpins against USP9x and observed that all
five decreased both endogenous and exogenous FOXO3a
protein levels (Fig. 6A,B; Supplemental Fig. S4G). Similar
results were obtained after transient transfection with
USP9x shRNA/siRNAs in MCF-7, T47D, and 293T cells
(Fig. 6C; Supplemental Fig. S4H,I). Moreover, we could
rescue FOXO3a levels in cells expressing an effective
USP9x shRNA by coexpressing an shRNA-resistant ver-
sion of USP9x (Fig. 6C). As expected, down-regulation
of FOXO3a in cells after shRNA-mediated USP9x de-
pletion reflected enhanced FOXO3a ubiquitylation and
decreased FOXO3a stability (Fig. 6D,E). In a complemen-
tary set of experiments, we found that exogenous expres-
sion of wild-type USP9x, but not a previously reported
catalytically inactive USP9x variant (C1556S) (Schwickart
et al. 2010; Xie et al. 2013), promoted the accumulation of
FOXO3a (Fig. 6F). Collectively, these results suggest that
USP9x promotes FOXO3a stability.
Although these results indicated that USP9x could
protect FOXO3a from ubiquitin-mediated proteolysis,
they did not address the importance of FOXO3a hydrox-
ylation in this process. To address this question, we next
transiently transfected T47D cells to produce either wild-
type HA-FOXO3a or the HA-FOXO3a variant in which
prolyl residues 426 and 437 were converted to alanine
(P426A;P437A) and treated them with MG132 in an
attempt to equalize the amount of exogenous FOXO3a.
We repeatedly detected increased coimmunoprecipita-
tion of USP9x with the P426A;P437A mutant relative
to wild-type FOXO3a (Fig. 6G). In a complementary set of
experiments, synthetic, biotinylated FOXO3a peptides
corresponding to FOXO3a residues 420–444 were used
to capture USP9x from T47D extracts, as determined by
immunoblot analysis. The 420–444 peptide readily cap-
tured USP9x unless either or both prolyl sites were
synthetically hydroxylated (Fig. 6H). Moreover, inhibi-
tion of EglN2 with prolyl hydroxylase inhibitors (DFO
and DMOG) (Fig. 6I) or an effective siRNA (Fig. 6J) did not
increase FOXO3a protein levels in T47D breast cancer
cells in which USP9x was depleted. The effects were
specific because loss of USP9x did not prevent the in-
duction of FOXO3a by MG132 (Fig. 6J). Collectively,
these results suggest that prolyl hydroxylation by EglN2
diminishes the binding of USP9x to FOXO3a, leading to
FOXO3a destabilization.
Discussion
We developed an in vitro hydroxylation screen that
identified FOXO3a as a potential EglN2 substrate and
found that EglN2 can hydroxylate FOXO3a on prolyl 426
and 437 sites in vitro and in vivo. FOXO3a hydroxylation
disrupts its interaction with the USP9x deubiquitinase.
The dissociation from USP9x promotes FOXO3a ubiqui-
tylation and proteasomal degradation (Fig. 7A). Loss of
EglN2 promotes the accumulation of FOXO3a as a result
of enhanced FOXO3a protein stability, which suppresses
Cyclin D1 expression (Fig. 7B).
Regulation of FOXO3a by EglN2 appears to be impor-
tant in signaling by estrogens. Activation of the estrogen
receptor a (ERa) by estrogens induces EglN2 mRNA (Seth
et al. 2002; Appelhoff et al. 2004; Zhang et al. 2009), and
EglN2 promotes mammary proliferation (Seth et al. 2002;
Zhang et al. 2009). Conversely, loss of EglN2 decreases
mammary gland proliferation during lactation and de-
creases the proliferation of estrogen-responsive breast
cancer cells in vitro and in vivo (Zhang et al. 2009). Our
findings suggest that these phenotypes are due at least
partly to EglN2’s role in the regulation of FOXO3a and its
downstream target, Cyclin D1, which plays a critical role
in mammary proliferation. Interestingly, FOXO3a has been
reported to control the transcription of ERa and, through
physical association, affect ERa-dependent transcription
(Guo and Sonenshein 2004). If true, this would suggest that
induction of EglN2 and down-regulation of FOXO3a con-
stitute a feedback loop with ERa.
Genetic studies in mice indicate that members of the
FOXO family, including FOXO3a, can act as tumor sup-
pressor genes. Somatic deletion of all three FOXOs (FOXO1,
FOXO3, and FOXO4) engenders a cancer-prone condition
in mice, further strengthening its tumor suppressor role
in vivo (Paik et al. 2007). Consistent with this, decreased
expression of FOXO3a associated with poor outcomes in
breast cancer and neuroblastoma (Sunayama et al. 2011;
Jiang et al. 2013; Santo et al. 2013). Conversely, FOXO3a
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nuclear localization is associated with good prognosis in
luminal-like breast cancer (Habashy et al. 2011). Moreover,
exogenous expression of FOXO3a inhibits tumor growth in
vitro and in vivo in breast cancer (Hu et al. 2004; Yang et al.
2008; Lin et al. 2011; Sisci et al. 2013).
It is well established that FOXO3a is regulated by phos-
phorylation on T32 and S253 by AKT/SGK kinase, which
creates binding sites for chaperone protein 14-3-3 (Brunet
et al. 1999, 2001, 2002; Huang and Tindall 2007). Binding to
14-3-3 promotes the translocation of FOXO3a from nucleus
to cytoplasm, where it undergoes proteasomal degradation
(Brunet et al. 2002). Similarly, it is also known that
phosphorylation of FOXO3a at S294, S344, and S425 by
ERK promotes the binding of MDM2 to FOXO3a, which
Figure 6. Differential binding of USP9x
underlies control of FOXO3a stability by
EglN2. (A) Immunoblot analysis of T47D
cells that were infected with a lentivirus
encoding the indicated USP9x shRNAs
or Ctrl shRNA. (B) Immunoblot analysis
of T47D cells that were infected with
a lentivirus encoding HA-FOXO3a and
then superinfected with a lentivirus encod-
ing USP9x shRNA (364 or 064) or Ctrl
shRNA. (C) Immunoblot analysis of 293T
cells that were infected with a lentivi-
rus encoding USP9x shRNA (364) or Ctrl
shRNA and then, after drug selection,
transfected with a plasmid encoding V5-
tagged mouse full-length USP9x or empty
vector (Ctrl). (D) Immunoblot (IB) assays of
whole-cell extracts (WCE) and immuno-
precipitates (IP) of T47D cells that were
infected with a lentivirus encoding USP9x
shRNA (sh128 or sh364) or Ctrl shRNA
and then, after drug selection, transiently
transfected with plasmids encoding Flag-
ubiquitin and HA-FOXO3a followed by
treatment with 10 mM MG132 for 16 h.
(E) Immunoblot analysis of MCF-7 cells
that were infected with a lentivirus encod-
ing shRNA against either USP9x (364)
or Ctrl shRNA followed by 100 mg/mL
cycloheximide for the indicated dura-
tion. (F) Immunoblot analysis of 293T
cells that were cotransfected with plas-
mids encoding V5-tagged USP9x (wild-
type or C1556S) and HA-FOXO3a. (G)
Immunoblot (IB) assays of whole-cell ex-
tracts (WCE) and immunoprecipitates (IP)
of T47D cells that were transfected with
a plasmid encoding HA-FOXO3a (wild-
type or P426A;P437A) followed by treat-
ment with 10 mM MG132 for 16 h. (H)
Immunoblot analysis of bound USP9x re-
covered from lysed T47D cells that were
incubated with 20 mL of Neutravidin-
Sepharose preloaded with the indicated
FOXO3a peptides. (I,J) Immunoblot analy-
sis of T47D cells that were infected with
a lentivirus encoding USP9x shRNA (364)
or Ctrl shRNA and then, after drug selec-
tion, treated with the indicated drugs or
siRNAs.
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likewise promotes its proteasomal degradation (Yang et al.
2008). Finally, phosphorylation of FOXO3a by IkB kinase
on S644 was reported to affect FOXO3a stability by
promoting the binding of b-TRCP E3 ligase (Hu et al.
2004; Tsai et al. 2010). Our findings reveal another layer to
the regulation of FOXO3a stability, in this case mediated
by changes in deubiquitylation rather than ubiquitylation.
USP9x appears to be capable of either enhancing or
suppressing tumor growth in a context-dependent man-
ner. For example, USP9x has been reported to stabilize
the anti-apoptosis protein Mcl-1 and promote tumor cell
survival in follicular lymphomas and diffuse large B-cell
lymphomas (Schwickart et al. 2010). On the other hand,
by using transposon-mediated insertional mutagenesis,
Tuveson and colleagues (Perez-Mancera et al. 2012) iden-
tified USP9x as a gene that, when inactivated, cooperates
with oncogenic Kras to accelerate pancreatic ductal
adenocarcinoma (PDA). Our studies show that loss of
USP9x leads to loss of FOXO3a. This would be predicted
to promote tumor growth in certain settings for the
reasons outlined above.
As an EglN2 substrate, FOXO3a is stabilized by hyp-
oxia and hypoxia mimetics. In addition, FOXO3a appears
to be a direct HIF target (Bakker et al. 2007; Jensen et al.
2011). FOXO3a clearly plays a role in adaptation to
hypoxic stress (Scott et al. 2002; Miyamoto et al. 2007;
Tothova and Gilliland 2007; Mabon et al. 2009; Jensen
et al. 2011). Induction of FOXO3a by hypoxia might help
conserve ATP by restricting cell proliferation as well as by
reprogramming cell metabolism. In this regard, FOXO3a
was reported to regulate oxygen consumption and reac-
tive oxygen species (ROS) production by inhibiting mito-
chondrial gene expression (Jensen et al. 2011; Ferber et al.
2012). FOXO3a activation by hypoxia could decrease
mitochondrial gene expression and mitochondria DNA
copy number, which could shift cellular metabolism from
oxidative phosphorylation to glycolysis and reduce oxi-
dative stress. In this way, FOXO3a would, like HIF, serve
as another important regulator mediating cellular adap-
tation to hypoxia. It is also possible that FOXO3a tunes
the HIF response in certain settings, as suggested before
(Bakker et al. 2007; Jensen et al. 2011). Notably, EglN2/
mice display decreased oxygen consumption and increased
hypoxia tolerance associated with increased expression of
pyruvate dehydrogenase 4 (PDK4), which is responsive to
FOXO3a (Kwon et al. 2004; Aragones et al. 2008).
It remains to be determined whether EglN2 has addi-
tional substrates, especially as our screen was restricted
to 1000 cDNAs. Moreover, we have not yet done second-
ary analyses of other potential positives from our screen,
such as the FOXO3a paralog FOXO1 and IkBKB. With
regard to IkBKB, Taylor and coworkers (Cummins et al.
2006) showed that EglN2 loss as well as hydroxylase
inhibitors activate NFkB and provided indirect evidence
that IkBKB was hydroxylated, including the presence of
a peptide sequence similar to the sequence that is prolyl-
hydroxylated in HIFa. However, they were unable to
confirm that EglN2 hydroxylates IkBKB. Our data suggest
that this question should now be revisited.
Strategies to induce FOXO3a signaling in cancer might
have therapeutic potential, especially in cancers such as
breast cancer in which expression of FOXO3a or loss of
Cyclin D1 inhibits cell proliferation. It has been argued
that certain cytotoxic drugs, such as Paclitaxel and
Imatinib, induce FOXO3a protein by indirectly promoting
FOXO3a dephosphorylation (Sunters et al. 2003, 2006;
Essafi et al. 2005). Targeted agents that block PI3K/AKT
signaling also induce FOXO3a (Sunters et al. 2006). Our
study opens another avenue for manipulating FOXO3a
activity. In particular, our work predicts that EglN2 in-
hibitors would promote the accumulation of FOXO3a and
in turn down-regulate Cyclin D1, leading to impaired can-
cer cell proliferation. In this regard, it has already been
established that EglN family members can be inhibited
with drug-like small organic molecules in humans (Nwogu
et al. 2001; Ivan et al. 2002; Fraisl et al. 2009; Beuck et al.
2012). It will be important to determine whether small
molecule EglN2 inhibitors display anti-cancer activity
either alone or when combined with other agents such as
cytotoxics, Cdk4 inhibitors, or PI3K/AKT inhibitors.
Figure 7. Proposed models for FOXO3a regulation by
EglN2. (A) Estrogen binding with ER transcriptionally
induces EglN2, which triggers FOXO3a hydroxylation
on prolyl residue 426 and 327 sites. Hydroxylation of
these sites dissociates FOXO3a from USP9x deubiqui-
tinase, thereby facilitating FOXO3a ubiquitylation and
degradation. (B) Depletion of EglN2 by either lack of ER
activity or EglN2 siRNAs/shRNAs prevents FOXO3a
from being hydroxylated. As a result, USP9x binds with
FOXO3a and prevents FOXO3a from being ubiquity-
lated and degraded. Stabilization of FOXO3a decreases
Cyclin D1 expression.
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Materials and methods
Cell culture
MEF, 293FT, and MCF-7 cells were cultured in DMEM containing
10% fetal bovine serum (FBS) plus 1% penicillin and streptomycin
(Pen Strep). BT474 and T47D cells were maintained in RPMI
medium containing 10% FBS plus 1% Pen Strep. Following
lentiviral infection, cells were maintained in the presence of 200
mg/mL hygromycin or 2 mg/mL puromycin, depending on the
vector. All cells were maintained at 37°C in 5% CO2.
Plasmids
Full-length HA-tagged FOXO3a was amplified by PCR with a 59
primer that introduced a NotI site and an HA tag and a 39 primer
that introduced a BamHI site. The PCR product was digested with
BamHI and NotI and cloned into pcDNA3.1(+) (Invitrogen) vec-
tor cut with these two enzymes. FOXO3a P426A, P437A, and
P426A;P437A cDNAs were generated by site-directed mutagenesis.
The FOXO3a insert was cut with BamHI and NotI and ligated into
pGEX-4T-2 (Amersham) vector cut with these two enzymes to
make the full-length GST-FOXO3a plasmid. The FOXO3a cDNA
encoding residues 301–674 was amplified by PCR with a 59 BamHI
and a 39 NotI site and ligated into pGEX-4T-2 vector cut with these
two enzymes to make the GST-FOXO3a (301–674) plasmid.
Full-length Flag-tagged EglN2 was amplified by PCR with a 59
primer that introduced an EcoRI site and a Flag tag and a 39 primer
that introduced a BamHI site. The PCR product was digested with
EcoRI and BamHI and cloned into pcDNA3.1() vector cut with
these two enzymes. Full-length human EglN2 was amplified by
PCR with a 59 BamHI and a 39 EcoRI site. The EglN2 PCR product
was digested with BamHI and EcoRI and ligated into pGEX-4T-2
vector to make the GST-EglN2 plasmid. pLenti6-Flag-EglN2 was
described previously (Koivunen et al. 2012). pLenti6-Flag-EglN2
(H358A) was generated by using site-directed mutagenesis. The
inducible expression plasmid for Flag-tagged EglN2 was generated
by PCR of EglN2 cDNA in pcDNA-HA-EglN2 plasmid with a 59
primer that introduced an XmaI and a Flag tag and a 39 primer that
introduced a ClaI site. The PCR product was digested with XmaI
and ClaI and cloned into pTripZ vector (Thermo Scientific) cut
with AgeI and ClaI. In order to generate shRNA-resistant EglN2
cDNAs, translationally silent mutations were introduced into
EglN2 shRNA recognition sites by site-directed mutagenesis as
indicated previously (Zhang et al. 2009).
The UBC Hygro HA-FOXO3a plasmids encoding full-length
FOXO3a, FOXO3a (1–200), FOXO3a (1–300), FOXO3a (1–500),
and FOXO3a (200–500) were made by PCR-amplifying a FOXO3a
cDNA with a 59 primer that introduced a BamHI site and an HA
tag and a 39 primer that introduced a NotI site. The PCR product
was digested with BamHI and NotI and ligated into pLenti-UBC-
pGK-Hyg (a modified version of pLL3.7, Addgene) vector cut
with these two enzymes. FasL and FHRE plasmids were obtained
from Addgene.
V5-tagged mouse USP9x, catalytic-dead USP9x C1556S, and
GST-tagged human USP9x (N1, N2, C1, and C2) plasmids were
generously provided by Dr. Feng Cong (Novartis). Human USP9x
cDNA fragments (N1, N2, C1, and C2) were subcloned into
pcDNA3.1 vector with an N-terminal Flag tag.
Plasmid pSP64polyA (Promega no. P1241) was modified to
allow for recombination subcloning of cDNAs from pDNR1r
plasmids (Clontech) using the Cre-loxP system and gain an N-
terminal RGS-6xHis tag; the final plasmid was intended to allow
for easy/effective in vitro transcription/translation of His-tagged
proteins using the SP6 promoter. All plasmids were confirmed by
DNA sequencing.
Generation of cDNA library in PSP64 PolyA vector
Glycerol stocks for ;1000 gateway-compatible donor plasmids
containing ORF cDNA previously linked to breast cancer were
obtained from the Harvard Institute for Proteomics (Witt et al.
2006). One-hundred nanograms of Miniprep DNA for these
clones was mixed with the destination vector pSP64PolyA
RGS-6HisLoxP (modified pSP64PolyA [Promega], which allows
for in vitro transcription and introduces an N-terminal RGS-
6His tag), 1 mL of CRE recombinase (New England Biolabs), and
CRE reaction buffer (33 mM NaCl, 50 mM Tris-HCl, and 10 mM
MgCl2) in a 10-mL reaction. The recombination reaction was
performed for 30 min at 37°C followed by 10 min of heat
inactivation at 70°C in a 96-well format. Five microliters of
each recombination reaction was then incubated with 20 mL of
competent E. coli followed by plating onto plates compatible
with ampicillin, chloramphenicol, and sucrose triple selection.
Miniprep DNA was isolated from surviving colonies and au-
thenticated by colony PCR.
Generation of recombinant EglN2
Full-length human EglN2 with C-terminal Flag and His tags was
expressed using a baculovirus in H5 insect cells and immuno-
purified with anti-Flag antibody, as previously described (Hirsila
et al. 2005).
In vitro decarboxylation assay
In vitro decarboxylation assay was modified from a previously
published in vitro hydroxylation assay (Zhang et al. 1999).
In brief, peptides or in vitro translated protein were supple-
mented with 50 mM HEPES (pH 7.4), 1500 U/mL catalase, 100
mM FeSO4, 1 mM ascorbic acid, 0.15 mCi/mL [1-
14C] a-KG
(Perkin Elmer), and 1 mg of purified recombinant EglN2 in
a 100-mL reaction volume in a 96-well format. Radiolabeled CO2
was captured with glass fiber filter paper (catalog no. IH-201-A,
Inotech Biosystems International) soaked with 30 mM satu-
rated Ca(OH)2. A plastic adhesive microtiter plate sealer film
was applied to the one side of the filter paper that was not
in contact with the plate. The plate and filter paper with
plastic sealer were sandwiched between two custom-made
aluminum plates. The upper plate had a protective rubber layer
that contacted the plastic-coated filter paper. The plate was
clamped together by hand-tightening four thumbscrews. The
clamped plate was transferred to a 37°C oven and allowed to
incubate for 2 h, after which the apparatus was disassembled.
The filter papers were dried under a heat lamp for 20 min
and exposed to storage phosphorscreens overnight. Images were
recorded using a Typhoon 8600 imager (Amersham Biosciences).
Arbitrary signal intensity was calculated by ImageQuant soft-
ware, with the background signal (empty vector control) being
subtracted.
Immunoprecipitation
Cells were lysed in in EBC lysis buffer supplemented with com-
plete protease inhibitors (Roche Applied Bioscience). The lysates
were clarified by centrifugation and then mixed with primary
antibodies or 3F10 anti-HA-conjugated beads (Roche Applied
Bioscience) overnight at 4°C. For primary antibodies, protein G
Sepharose was added for an additional 2 h (Roche Applied
Bioscience). The bound complexes were washed with NETN
buffer eight times and were eluted by boiling in SDS loading
buffer. Bound proteins were resolved in SDS-PAGE followed by
immunoblot analysis.
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Peptide synthesis
All peptides were synthesized at the W.M. Keck Biotechnology
Resource Center at Yale University. Each contained an N-terminal
biotin and free C terminus and was synthesized in 25 mM scale.
The sequences were as follows: HIF1a (556–575), DLDLEMLAP
YIPMDDDFQLR; HIF1a P564-OH, DLDLEMLAP#YIPMDDDF
QLR (# denotes hydroxylation); FOXO3a (400–440), QPSPTGG
LMQRSSSFPYTTKGSGLGSPTSSFNSTVFGPSSL; FOXO3a (420–
444), GSGLGSPTSSFNSTVFGPSSLNSLR; P426-OH, GSGLGSP#
TSSFNSTVFGPSSLNSLR (# denotes hydroxylation); P437-OH,
GSGLGSPTSSFNSTVFGP#SSLNSLR (# denotes hydroxylation);
and P426-OH;P437-OH, GSGLGSP#TSSFNSTVFGP#SSLNSLR
(# denotes hydroxylation).
GST protein purification and GST pull-down
GST plasmids were transformed with BL21-competent cells.
Single colonies were picked and cultured overnight in 50 mL of
LB medium containing ampicillin. Five milliliters of overnight
culture was diluted into 500 mL of fresh LB medium with
ampicillin and grown for 2–3 h at 37°C with shaking until
OD600 reached 0.8–1.0, at which point 0.2 mM IPTG was added
to induce GST protein production. Four hours later, the bacteria
were pelleted by centrifugation and disrupted by a nanodebee
homogenizer. Cleared bacteria lysates were purified using
Glutathione-Sepharose 4B. Twenty microliters of Glutathione-
Sepharose 4B preloaded with ;2 mg of recombinant protein of
GST fusion proteins was incubated with either in vitro trans-
lated protein in 500 mL of NETN buffer or EBC cell lysates. Af-
ter overnight incubation, bound complexes were washed eight
times with NETN buffer times followed by boiling in SDS
loading buffer and SDS-PAGE.
Peptide-binding assay
Peptides (50 mg) were incubated with 20 mL of Neutravidin-
Sepharose (Pierce) and 500 mg of EBC extracts prepared from
T47D parental cells or T47D cells expressing Flag-EglN2 in
a total volume of 500 mL overnight at 4°C. The Sepharose was
washed eight times with NETN buffer. Bound proteins were then
eluted by boiling in SDS loading buffer, resolved by SDS-PAGE,
and detected by immunoblot analysis.
Mice
EglN2/mice were generously provided by Regeneron Pharma-
ceuticals. MEFs were isolated from embryonic day 13.5 (E13.5) as
described previously (Zhang et al. 2009). EglN1Flox/Flox (F/F) mice
were described previously (Minamishima et al. 2008; Moslehi
et al. 2010). All experiments related to mice complied with
National Institutes of Health guidelines and were approved by
the Animal Care and Use Committees at either the Dana-Farber
Cancer Institute or University of North Carolina at Chapel Hill.
Western blot analysis and antibodies
EBC buffer (50 mM Tris-HCl at pH 8.0, 120 mM NaCl, 0.5%
NP40, 0.1 mM EDTA, and 10% glycerol) supplemented with
complete protease inhibitor (Roche Applied Biosciences) was
used to harvest whole-cell lysates. Mouse mammary glands and
tumor tissues were lysed in 8 M urea containing 40 mM Tris-HCl
(pH 7.6) and 2.5 mM EDTA. Cell lysate concentrations were
measured by Bradford assay. Equal amounts of cell lysates were
resolved by SDS-PAGE. Rabbit anti-FOXO3a (no. 2497), P-OH
HIF564 (no. 3434), FOXO1 (no. 2880), EglN1 (no. 4835), p-AKT473
(no. 9271), and AKT (no. 9272) antibodies were obtained from
Cell Signaling. Rabbit anti-EglN2 (no. NB100-310) and HIF1a
(no. NB100-479) antibodies were obtained from Novus Biologi-
cal. Rabbit anti-Cyclin D1 antibody (no. RB-010-P0) was
obtained from Neomarker. Mouse anti-ARNT (no. 611079) and
HIF1a (no. 610958) antibodies were obtained from BD Biosci-
ence. Anti-HA antibody (no. MMS-101P) was obtained from
Covance. Anti-vinculin (no. V9131), tubulin (no. T9026), and Flag
(M2, no. F3165) antibodies were obtained from Sigma. Anti-V5
antibody (no. R960-25) was obtained from Invitrogen. Anti-USP9x
(no. A301-350) and anti-ubiquitin (no. A300-317A) antibodies
were obtained from Bethyl Laboratory. Anti-GST (no. SC-138)
antibody was obtained from Santa Cruz Biotechnology. The pan-
hydroxylated proline antibody was obtained from Advanced
Targeting Systems (no. AB-T044). Peroxidase-conjugated goat
anti-mouse secondary antibody (no. 31430) and peroxidase-
conjugated goat anti-rabbit secondary antibody (no. 31460) were
obtained from Thermo Scientific.
In vivo and in vitro mass spectrometry
For in vitro mass spectrometry, 2 mg of GST-HIF1a or GST-
FOXO3a (301–674) was incubated in 50 mM Tris-HCl (pH 7.8),
100 mM dithiothreitol (DTT), 1500 U/mL catalase, 10 mM FeSO4,
1 mM ascorbic acid, 0.2 mM a-KG, and 2 mg recombinant EglN2
enzyme in 100-mL reactions. The reaction tubes were incubated
for 1 h at 37°C. Samples were resolved by SDS-PAGE followed by
Coomassie staining. Bands corresponding to GST-HIF1a and
GST-FOXO3a were excised for mass spectrometry.
For in vivo mass spectrometry, eight p100 dishes of 293FT
cells were cotransfected with plasmids encoding Flag-EglN2
and either HA-HIF1a or HA-FOXO3a. Thirty-six hours post-
transfection, cells were treated with 10 mM MG132 for 16 h
before harvesting. Cleared cell lysates were incubated with
anti-HA-agarose (3F10, Roche Applied Science) followed by four
to five washes with NETN lysis buffer (120 mM NaCl, 20 mM
Tris-HCl at pH 8.0, 0.5 mM EDTA, 0.5% [v/v] Nonidet P-40
[NP-40]). Proteins were eluted by boiling in SDS-containing
sample buffer, resolved by SDS-PAGE, and identified by Coomassie
staining. HIF1a and FOXO3a bands were excised for mass
spectrometry.
The bands containing HIF1a or FOXO3a were reduced with 10
mM DTT for 30 min, alkylated with 55 mM iodoacetamide for
45 min, and in-gel-digested with trypsin enzymes. The resulting
peptides were extracted from the gel and analyzed by nanoscale-
microcapillary reversed-phase liquid chromatography-tandem
mass spectrometry (LC-MS/MS) as described previously (Villen
et al. 2008). All peptide matches were filtered based on mass
deviation, tryptic state, XCorr, and dCn and confirmed by
manual validation.
siRNAs and lentiviral shRNA vectors
Nontargeting control siRNA number 2 was obtained from
Dharmacon (catalog no. D0012100220). FOXO3a siRNA was
obtained from Cell Signaling Technology (catalog no. 6302).
EglN2 (1) and EglN2 (4) siRNAs were described previously (Zhang
et al. 2009): USP9x si1 target sequence, CGCCTGATTCTTC
CAATGAAA; and USP9x si2 target sequence, GTACGACGATG
TATTCTCA. EglN2 shRNA in pCCLsin.PPT.hPGK.GFP.Wpre
lentiviral vector was described previously (Zhang et al. 2009).
Lentiviral EglN2 shRNAs, ARNT shRNAs, and USP9x shRNAs
were obtained from Broad Institute TRC shRNA library. Target
sequences are listed as follows: Ctrl shRNA, CAACAAGATGAA
GAGCACCAA; EglN2 (325), GCTGCATCACCTGTATCTATT;
EglN2 (326), GCCACTCTTTGACCGGTTGCT; EglN2 (327),
ACTGGGACGTTAAGGTGCATG; ARNT (1770), GAGAAGT
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CAGATGGTTTATTT; ARNT (3146), CCTTTGTCTTTCTGT
GTACTT; USP9x (064), GGTCGTTACAGCTAGTATTTA; USP9x
(362), CGATTCTTCAAAGCTGTGAAT; USP9x (363), CGACCC
TAAACGTAGACATTA; USP9x (364), CGCCTGATTCTTCCA
ATGAAA; USP9x (128), GAGAGTTTATTCACTGTCTTA; and
FOXO3a shRNA, CATGTTCAATGGGAGCTTGGA.
Virus production and infection
Lentiviral infection was carried out essentially as previously
described (Moffat et al. 2006). Briefly, 293T cells were transfected
with Lipofectamine 2000, and viruses were collected 48 and 72 h
later. After passing through a 0.45-mM filter, virus supernatants
were used to infect target cells in the presence of 8 mg/mL
polybrene.
Cell culture luciferase assays
T47D cells and their derivatives were plated on a 24-well plate
and transfected with 150 ng of either FasL or FHRE reporter
plasmid (Addgene), 10 ng of the TK-Renilla luciferase expression
plasmid (Promega), and 500 ng of pcDNA or pcDNA Flag-EglN2
(EglN2 shRNA resistant) with Lipofectamine 2000 (Invitrogen)
reagent according to the manufacturer’s instructions. Thirty-six
hours later, luciferase activity of cells extracts was measured
with the Dual Luciferase assay system (Promega) according to
the manufacturer’s instructions and a Berthold Technologies
luminometer.
Cycloheximide pulse chase assay
For cycloheximide assays, cells were treated with 100 mg/mL
cycloheximide (Sigma) in appropriate growth medium. At vari-
ous times thereafter, cells were lysed and subjected to immuno-
blot analysis.
FOXO3a ubiquitylation assay
Twenty-four hours after transfection T47D cells were treated
with 5 mM MG132 overnight and then lysed in TBS plus 1% SDS.
Cell lysates were boiled for 10 min followed by addition of 1 mL
of EBC lysis buffer (with protease inhibitor cocktail) and sonica-
tion. Samples were chilled for 20 min on ice before anti-HA
conjugated Sepharose (3F10, Roche Applied Bioscience) was
added into each sample. Following incubation for 4 h at 4°C
with gentle mixing, the Sepharose was washed three times with
1 mL of prelysis buffer (20 mM Tris-HCl at pH 7.4, 650 mM
NaCl, 1 mM EDTA, 1% Triton X-100). The proteins were eluted
by boiling in SDS-containing sample buffer and resolved by SDS-
PAGE prior to immunoblot analysis.
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